Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia

Yoshihiro Tambo; Shinya Kajiura; Akihiro Yoshida; Shingo Chikaoka; Yuki Tanabe; Nahoko Kanai; Ando Takayuki; Akira Ueda; Iori Moto; Yurika Nakayama; Tomoko Shima; Yukiko Matsushita; Tatsuji Mizukami; Mosaburou Kainuma; Ichiro Yasuda; Ryuji Hayashi

doi:10.1089/jpm.2024.0050

Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia

Yoshihiro Tambo, Shinya Kajiura^*, Akihiro Yoshida, Shingo Chikaoka, Yuki Tanabe, Nahoko Kanai, Ando Takayuki, Akira Ueda, Iori Moto, Yurika Nakayama, Tomoko Shima, Yukiko Matsushita, Tatsuji Mizukami, Mosaburou Kainuma, Ichiro Yasuda, Ryuji Hayashi

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

Background: The commercial availability of anamorelin, Japan’s first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. Objective: We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. Methods: A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Results: Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Conclusion: Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin’s therapeutic benefits.

Original language	English
Pages (from-to)	922-925
Number of pages	4
Journal	Journal of Palliative Medicine
Volume	27
Issue number	7
DOIs	https://doi.org/10.1089/jpm.2024.0050
State	Published - 2024/07/01

Keywords

meal intake
pancreatic cancer
retrospective study

ASJC Scopus subject areas

General Nursing
Anesthesiology and Pain Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1089/jpm.2024.0050

Cite this

Tambo, Y., Kajiura, S., Yoshida, A., Chikaoka, S., Tanabe, Y., Kanai, N., Takayuki, A., Ueda, A., Moto, I., Nakayama, Y., Shima, T., Matsushita, Y., Mizukami, T., Kainuma, M., Yasuda, I., & Hayashi, R. (2024). Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia. Journal of Palliative Medicine, 27(7), 922-925. https://doi.org/10.1089/jpm.2024.0050

@article{9560b25863274ef48b833c9ac242535b,

title = "Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia",

abstract = "Background: The commercial availability of anamorelin, Japan{\textquoteright}s first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. Objective: We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. Methods: A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Results: Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Conclusion: Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin{\textquoteright}s therapeutic benefits.",

keywords = "meal intake, pancreatic cancer, retrospective study",

author = "Yoshihiro Tambo and Shinya Kajiura and Akihiro Yoshida and Shingo Chikaoka and Yuki Tanabe and Nahoko Kanai and Ando Takayuki and Akira Ueda and Iori Moto and Yurika Nakayama and Tomoko Shima and Yukiko Matsushita and Tatsuji Mizukami and Mosaburou Kainuma and Ichiro Yasuda and Ryuji Hayashi",

note = "Publisher Copyright: {\textcopyright} Mary Ann Liebert, Inc.",

year = "2024",

month = jul,

day = "1",

doi = "10.1089/jpm.2024.0050",

language = "英語",

volume = "27",

pages = "922--925",

journal = "Journal of Palliative Medicine",

issn = "1096-6218",

publisher = "Mary Ann Liebert Inc.",

number = "7",

}

TY - JOUR

T1 - Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia

AU - Tambo, Yoshihiro

AU - Kajiura, Shinya

AU - Yoshida, Akihiro

AU - Chikaoka, Shingo

AU - Tanabe, Yuki

AU - Kanai, Nahoko

AU - Takayuki, Ando

AU - Ueda, Akira

AU - Moto, Iori

AU - Nakayama, Yurika

AU - Shima, Tomoko

AU - Matsushita, Yukiko

AU - Mizukami, Tatsuji

AU - Kainuma, Mosaburou

AU - Yasuda, Ichiro

AU - Hayashi, Ryuji

PY - 2024/7/1

Y1 - 2024/7/1

N2 - Background: The commercial availability of anamorelin, Japan’s first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. Objective: We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. Methods: A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Results: Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Conclusion: Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin’s therapeutic benefits.

AB - Background: The commercial availability of anamorelin, Japan’s first therapeutic agent for cancer cachexia in 2021, led to an investigation into its prescription patterns at Toyama University Hospital. Objective: We aimed to analyze anamorelin prescription trends and outcomes among cancer cachexia patients. Methods: A retrospective study from July 2021 to December 2022 examined 88 cases, assessing demographics, cancer types, prescription locations, and meal intake changes. Results: Anamorelin usage was predominant during chemotherapy, especially for pancreatic cancer in outpatient settings. Approximately 30% experienced increased meal intake. Chemotherapy-initiated cases had a longer median duration (55 days) compared with best supportive care only cases (12 days). Conclusion: Anamorelin demonstrated significant prescription patterns, particularly during chemotherapy for pancreatic cancer in outpatient settings, suggesting potential efficacy enhancements when administered with chemotherapy in cancer cachexia management. The study underscores the importance of tailored approaches to optimize anamorelin’s therapeutic benefits.

KW - meal intake

KW - pancreatic cancer

KW - retrospective study

UR - http://www.scopus.com/inward/record.url?scp=85197404877&partnerID=8YFLogxK

U2 - 10.1089/jpm.2024.0050

DO - 10.1089/jpm.2024.0050

M3 - 学術論文

C2 - 38949886

AN - SCOPUS:85197404877

SN - 1096-6218

VL - 27

SP - 922

EP - 925

JO - Journal of Palliative Medicine

JF - Journal of Palliative Medicine

IS - 7

ER -

Prescription Pattern of Anamorelin; a Therapeutic Agent for Cancer Cachexia

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Cite this